-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Beta Bionics with Neutral Rating, Announces Price Target of $16

Benzinga·05/30/2025 18:16:35
Listen to the news
Goldman Sachs analyst David Roman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Neutral rating and announces Price Target of $16.